ReviewClinical pharmacology and therapeutics2020
Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19.
Review in Clinical pharmacology and therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 2 syntheses or guidelines pooled it, 178 citations in OpenAlex.
- Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials.Reviews in medical virology · 2022Pooled it
- The management of surgical patients in the emergency setting during COVID-19 pandemic: the WSES position paper.World journal of emergency surgery : WJES · 2021Guideline
- Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance.International journal of antimicrobial agents · 2021Trial
- Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A natural clinical trial.International journal of clinical practice · 2021Trial
- Reduction of Coronavirus Burden With Mass Azithromycin Distribution.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Trial
- Antimicrobial Consumption and Prescribing Patterns in Hospitalized Children During and After the COVID-19 Pandemic.Pathogens (Basel, Switzerland) · 2026Article
- A Nationwide Evaluation of Antibiotic Consumption in Kazakhstan from 2019 to 2023.Antibiotics (Basel, Switzerland) · 2024Article
- Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period.Signal transduction and targeted therapy · 2023Review
- Prevalence and reasons for self-medication for prevention of COVID-19 among the adult population in Kermanshah-Iran.Nursing open · 2023Article
- Antihistamines as an early treatment for Covid-19.Heliyon · 2023Article
- A Review of Antibiotic Efficacy in COVID-19 Control.Journal of immunology research · 2023Review
- Local Delivery of Azithromycin Nanoformulation Attenuated Acute Lung Injury in Mice.Molecules (Basel, Switzerland) · 2022Article
- A Cross-Sectional Analysis of Self-Medication Patterns during the COVID-19 Pandemic in Ecuador.Medicina (Kaunas, Lithuania) · 2022Article
- Assessment of A new Strategy to Prevent Prescribing Errors Involving COVID-19 Patients in Community Pharmacies.Hospital pharmacy · 2022Article
- Azithromycin through the Lens of the COVID-19 Treatment.Antibiotics (Basel, Switzerland) · 2022Review
- Effect of Administration of Azithromycin and/or Probiotic Bacteria on Bones of Estrogen-Deficient Rats.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Effects of azithromycin on ventricular repolarization in children with COVID-19.Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology · 2022Article
- BCG Vaccination: A potential tool against COVID-19 and COVID-19-like Black Swan incidents.International immunopharmacology · 2022Review
- Review
- Effects of Drugs Formerly Suggested for COVID-19 Repurposing on Pannexin1 Channels.International journal of molecular sciences · 2022Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Azithromycin (AZ) is a broad-spectrum macrolide antibiotic with a long half-life and a large volume of distribution. It is primarily used for the treatment of respiratory, enteric, and genitourinary bacterial infections. AZ is not approved for the treatment of viral infections, and there is no well-controlled, prospective, randomized clinical evidence to support AZ therapy in coronavirus disease 2019 (COVID-19). Nevertheless, there are anecdotal reports that some hospitals have begun to include AZ in combination with hydroxychloroquine or chloroquine (CQ) for treatment of COVID-19. It is essential that the clinical pharmacology (CP) characteristics of AZ be considered in planning and conducting clinical trials of AZ alone or in combination with other agents, to ensure safe study conduct and to increase the probability of achieving definitive answers regarding efficacy of AZ in the treatment of COVID-19. The safety profile of AZ used as an antibacterial agent is well established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.